Writer and director Rick Famuyiwa attends the Los Angeles premiere of "Dope" at Premiere House at the Regal Cinemas L. A. LIVE in downtown Los Angeles on June 8, 2015. Famuyiwa exited Warner Bros. upcoming solo "Flash" film starring Ezra Miller. File Photo by Christine Chew/UPI | License Photo
LOS ANGELES, Nov. 1 (UPI) -- Director Rick Famuyiwa has exited Warner Bros. upcoming superhero epic The Flash as preproduction is underway.
According to Variety, citing sources close to the studio and Famuyiwa, the filmmaker departed the project over creative differences.
Known for helming 2015 Sundance favorite Dope, Famuyiwa released a statement on his departure noting, "When I was approached by Warner Bros. and DC about the possibility of directing The Flash, I was excited about the opportunity to enter this amazing world of characters that I loved growing up, and still do to this day."
"I was also excited to work with Ezra Miller, who is a phenomenal young actor. I pitched a version of the film in line with my voice, humor and heart. While it's disappointing that we couldn't come together creatively on the project, I remain grateful for the opportunity. I will continue to look for opportunities to tell stories that speak to a fresh generational, topical and multicultural point of view. I wish Warner Bros., DC, Jon Berg, Geoff Johns and Ezra Miller all the best as they continue their journey into the speed force," he continued.
Filming on The Flash was set to begin in early 2017 with Miller appearing alongside Dope star Kiersey Clemons as love interest Iris West and Billy Crudup in a key role.
Production could be delayed however Miller will appear as the Scarlet Speedster in Warner Bros. Justice League out Nov. 17.
Famuyiwa is the second to depart The Flash following the exit of Seth Grahame-Smit who was set to make his directorial debut with the film after writing popular novels Pride & Prejudice & Zombies and Abraham Lincoln: Vampire Hunter before adapting them into screenplays.
Grahame-Smith had written a script based on a treatment from Phil Lord and Christopher Miller.